Findings from a phase 1 trial demonstrate that silmitasertib shows potential for the treatment of patients with advanced ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Senhwa Biosciences announces positive data from phase 1/expansion trial of Silmitasertib for basal cell carcinoma treatment: Taipei, Taiwan Thursday, April 3, 2025, 15:00 Hrs [IST ...

Findings from an earlier trial of the Eli Lilly drug, called lepodisiran, showed the drug was safe. The latest study, a Phase ...

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Sensei Biotherapeutics' solnerstotug shows a 14% ORR in PD-(L)1 resistant tumors and remains well tolerated in early trial data from its Phase 1/2 study.

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 ...